Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Gross Margin for 4 consecutive years, with 34.84% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin fell 388.0% to 34.84% in Q3 2025 year-over-year; TTM through Sep 2025 was 27.86%, a 717.0% decrease, with the full-year FY2024 number at 36.09%, up 483.0% from a year prior.
  • Gross Margin was 34.84% for Q3 2025 at bioAffinity Technologies, up from 19.92% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 93.74% in Q2 2023 to a low of 0.29% in Q2 2022.
  • A 4-year average of 49.17% and a median of 36.78% in 2024 define the central range for Gross Margin.
  • Biggest YoY gain for Gross Margin was 9403bps in 2023; the steepest drop was -6776bps in 2023.
  • bioAffinity Technologies' Gross Margin stood at 92.54% in 2022, then tumbled by -73bps to 24.78% in 2023, then grew by 18bps to 29.24% in 2024, then increased by 19bps to 34.84% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Gross Margin are 34.84% (Q3 2025), 19.92% (Q2 2025), and 26.21% (Q1 2025).